Cue Biopharma Announces Data From CUE-401 Demonstrates All Dose Levels In Murine, NHP Trials Were Tolerated, No Adverse Events Reported

Cue Biopharma, Inc. -6.74% Pre

Cue Biopharma, Inc.

CUE

0.28

0.28

-6.74%

-2.43% Pre

Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today announced preclinical safety and tolerability data that further supports the preclinical profile of CUE-401, the Company's lead autoimmune asset.

Two separate non-GLP studies in mice and non-human primates (NHPs) assessed the safety and tolerability of CUE-401 using a step-up dosing schedule, where animals successively received higher doses of CUE-401, weekly. CUE-401 was administered intravenously.

Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via